IP Library Granted Patent US 7,541,185
Granted Patent B2
US 7,541,185 · App. 11/165,305 · Granted Jun 2, 2009

Methods for identifying factors for differentiating definitive endoderm

Assignee: Cythera, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,541,185
App. No.
11/165,305
Granted
Jun 2, 2009
Kind
B2
Abstract

Disclosed herein are methods of identifying one or more differentiation factors that are useful for differentiating cells in a cell population comprising definitive endoderm cells into cells which are capable of forming tissues and/or organs that are derived from the gut tube.

Claims (36)

1. A method of identifying a factor that promotes the differentiation of human definitive endoderm cells, said method comprising the steps of:

obtaining a human cell population comprising human definitive endoderm cells, wherein said human definitive endoderm cells comprise at least 10% of the human cells in said cell population;

providing a candidate differentiation factor to said cell population;

determining expression of a marker of a cell differentiated from definitive endoderm in said cell population at a first time point;

determining expression of the same marker in said cell population at a second time point, wherein said second time point is subsequent to said first time point and wherein said second time point is subsequent to providing said cell population with said candidate differentiation factor; and

determining if expression of the marker in said cell population at said second time point is increased as compared to the expression of the marker in said definitive endoderm cell population at said first time point, wherein an increase in expression of said marker in said cell population indicates that said candidate differentiation factor promotes the differentiation of said human definitive endoderm cells.

2. The method of claim 1 , wherein human feeder cells are present in said cell population and wherein at least 10% of the human cells other than said feeder cells are definitive endoderm cells.

3. The method of claim 1 , wherein said human definitive endoderm cells comprise at least 90% of the human cells in said cell population.

4. The method of claim 1 , wherein said human feeder cells are present in said cell population and wherein at least 90% of the human cells other than said feeder cells are definitive endoderm cells.

5. The method of claim 1 , wherein said marker is selected from the group consisting of pancreatic-duodenal homeobox factor-1 (PDX1), homeobox A13 (HOXA13) and homeobox C6 (HOXC6) in response to said candidate differentiation factor.

6. The method of claim 1 , wherein said marker is selected from the group consisting of albumin, prospero-related homeobox 1 (PROX1) and hepatocyte specific antigen (HSA) in response to said candidate differentiation factor.

7. The method of claim 1 , wherein said marker is thyroid transcription factor 1 (TITF1) in response to said candidate differentiation factor.

8. The method of claim 1 , wherein said marker is selected from the group consisting of villin and caudal type homeobox transcription factor 2 (CDX2)) in response to said candidate differentiation factor.

9. The method of claim 1 , wherein said first time point is prior to providing said candidate differentiation factor to said cell population.

10. The method of claim 1 , wherein said first time point is at approximately the same time as providing said candidate differentiation factor to said cell population.

11. The method of claim 1 , wherein said first time point is subsequent to providing said candidate differentiation factor to said cell population.

12. The method of claim 1 , wherein expression of said marker is increased.

13. The method of claim 1 , wherein expression of said marker is determined by quantitative polymerase chain reaction (Q-PCR).

14. The method of claim 1 , wherein expression of said marker is determined by immunocytochemistry.

15. The method of claim 1 , wherein said candidate differentiation factor comprises a small molecule.

16. The method of claim 1 , wherein said candidate differentiation factor comprises a retinoid.

17. The method of claim 1 , wherein said candidate differentiation factor comprises retinoic acid.

18. The method of claim 1 , wherein said candidate differentiation factor comprises a polypeptide.

19. The method of claim 1 , wherein said candidate differentiation factor comprises a growth factor.

20. The method of claim 1 , wherein said candidate differentiation factor comprises FGF-10.

21. The method of claim 1 , wherein said candidate differentiation factor comprises FGF-2.

22. The method of claim 1 , wherein said candidate differentiation factor comprises Wnt3B.

23. The method of claim 1 , wherein said candidate differentiation factor is not a foregut differentiation factor.

24. The method of claim 1 , wherein said candidate differentiation factor is not a retinoid.

25. The method of claim 1 , wherein said candidate differentiation factor is not retinoic acid.

26. The method of claim 1 , wherein said candidate differentiation factor is provided to said cell population at a concentration of between 0.1 ng/ml to 10 mg/ml.

27. The method of claim 1 , wherein said candidate differentiation factor is provided to said cell population at a concentration of between 1 ng/ml to 1 mg/ml.

28. The method of claim 1 , wherein said candidate differentiation factor is provided to said cell population at a concentration of between 10 ng/ml to 100 μg/ml.

29. The method of claim 1 , wherein said candidate differentiation factor is provided to said cell population at a concentration of between 100 ng/ml to 10 μg/ml.

30. The method of claim 1 , wherein said candidate differentiation factor is provided to said cell population at a concentration of 1 μg/ml.

31. The method of claim 1 , wherein said candidate differentiation factor is provided to said cell population at a concentration of 100 ng/ml.

Assignments (2)
MERGER Recorded May 9, 2011
From: CYTHERA, INC.
To: VIACYTE, INC.
Reel/Frame 026256/0656 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2006
From: D'AMOUR, KEVIN ALLEN; AGULNICK, ALAN D.; ELIAZER, SUSAN; BAETGE, EMMANUEL E.
To: CYTHERA, INC.
Reel/Frame 018483/0381 →
Continuity (8)
Continuation In Part 1111586800 · Apr 26, 2005
Continuation In Part 1116530500 · Jun 23, 2005
Continuation In Part 1102161800 · Dec 23, 2004
Provisional Application 6056629300 · Apr 27, 2004
Provisional Application 6058794200 · Jul 14, 2004
Provisional Application 6058656600 · Jul 9, 2004
Provisional Application 6053200400 · Dec 23, 2003
Related Publication 20060003313A1 · Jan 5, 2006